AC Immune, a biopharmaceutical company developing innovative therapeutics, to acquire Affiris PD01, a clinically-validated active vaccine candidate for the treatment of Parkinson’s disease, as well as cash, from Affiris, a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients, for $58.7m. “The transaction also allows us to focus on the partnering for further development of AFFiRiS’ other programs in cardiometabolic and neurodegenerative disease indications, such as candidates targeting PCSK9 in hypercholesterolemia and the monoclonal antibody C6-17 to treat Huntington’s disease,” Noel Barrett, AFFiRiS CEO.